WESTON, Fla., Nov. 4, 2016
WESTON, Fla., Nov. 4, 2016 /PRNewswire/ -- Apotex Corp. announced today the extension of the Imatinib Instant Savings* Card Program. The Instant Savings* Card Program extension was made to ensure that Apotex is assisting as many qualified patients to have access to Imatinib.
The extension ensures Imatinib Instant Savings* Card Program benefits are available to qualified new patients as well as currently enrolled patients through December 31, 2016.
The Imatinib Instant Savings* Card Program website (www.ImatinibZeroCopay.com) is designed to provide patients and prescribers detailed information about the benefits of enrolling in the Imatinib Instant Savings* Card Program as well as Imatinib Mesylate Tablet product information. Patients can learn more about the Imatinib Instant Savings* Card Program by visiting the website or calling toll free 877-336-2187.
Apotex launched Imatinib Mesylate Tablets, the generic equivalent of Gleevec® by Novartis in 100mg and 400mg strengths earlier this year. According to IMS Health, Gleevec® had approximately $2.4 billion in sales in the 12 months ending in May 2016.
Extending Apotex's Imatinib Instant Savings* Card Program is just another example of how Apotex is everywhere. Making a difference. One life at a time.
For safety information of Imatinib Mesylate Tablets please refer to U.S. Full Prescribing Information at www.ImatinibZeroCopay.com
Apotex Inc. is the 7th largest generic pharmaceutical company globally (according to IMS Health) with over 10,500 employees and estimated sales of approximately $2 billion. The company's US headquarters is based in Weston, Florida. With worldwide manufacturing sites, Apotex can produce up to 24 billion dosages per year. The majority of Apotex sites, including manufacturing, are in North America. Apotex produces 300 medicines in 4,000 dosages and formats that are exported to 115 countries. Apotex has 500 products under development and will spend $2 billion over the next 10 years on research and development.
For more information please visit us at www.apotexcorp.com or
Steve Giuli, Vice President Government Affairs and Trade Relations
*By using the Imatinib Instant Savings* Program you acknowledge meeting the eligibility requirements and complying with our terms and conditions below:
Apotex reserves the right, at its sole discretion, to amend, rescind, revoke, or terminate the program at any time.
Gleevec® is a registered trademark of Novartis AG Corporation, Switzerland.
This content was issued through the press release distribution service at Newswire.com. For more info visit: http://www.newswire.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/apotex-imatinib-instant-savings-card-program-extended-300357673.html
SOURCE Apotex Corp.PR Newswire
Last updated on: 04/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.